Molecular mechanisms of spinal muscular atrophy

Journal of Child Neurology

Volumn 22, Issue 8, 2007, Pages 979-989

  Sumner, Charlotte J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Motor neuron; Spinal muscular atrophy; Survival motor neuron

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; BUTYRIC ACID; CIS ACTING ELEMENT; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TRANS ACTING FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID;

ALTERNATIVE RNA SPLICING; ARTICLE; EXON; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; INTRON; MOLECULAR MECHANICS; MOTOR UNIT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPINAL MUSCULAR ATROPHY;

ALTERNATIVE SPLICING; CELL SURVIVAL; CHILD; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENETIC PREDISPOSITION TO DISEASE; HISTONE DEACETYLASES; HUMANS; MUTATION; NERVE TISSUE PROTEINS; RIBONUCLEOPROTEINS, SMALL NUCLEAR; RNA-BINDING PROTEINS; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD;

EID: 34548145188     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073807305787     Document Type: Article

References (74)

1. Brzustowicz LM, Lehner T., Castilla LH, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature. 1990;344:540-541.
2. Melki J., Sheth P., Abdelhak S., et al. Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators. Lancet. 1990;336:271-273.
3. Lefebvre S., Burglen L., Reboullet S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155-165.
4. Lorson CL, Hahnen E., Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96:6307-6311.
5. Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the spinal muscular atrophy gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8:1177-1183.
6. Lefebvre S., Burlet P., Liu Q., et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16:265-269.
7. Coovert DD, Le TT, McAndrew PE, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6:1205-1214.
8. Gavrilov DK, Shi X., Das K., et al. Differential SMN2 expression associated with spinal muscular atrophy severity. Nat Genet. 1998;20:230-231.
9. Soler-Botija C., Cusco I., Caselles L., et al. Implication of fetal SMN2 expression in type I spinal muscular atrophy pathogenesis: Protection or pathological gain of function? J Neuropathol Exp Neurol. 2005;64:215-223.
10. Parsons DW, McAndrew PE, Iannaccone ST, et al. Intragenic telSMN mutations: Frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet. 1998;63:1712-1723.
11. Feldkotter M., Schwarzer V., Wirth R., et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358-368.
12. Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A. 2004;130:307-310.
13. Wirth B., Brichta L., Schrank B., et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119:422-428.
14. Monani UR, Sendtner M., Coovert DD, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet. 2000;9:333-339.
15. Sumner C., Kolb SJ, Harmison GG, et al. SMN mRNA and protein levels in peripheral blood: Biomarkers for spinal muscular atrophy clinical trials. Neurology. 2006;66:1067-1073. Epub 2006 Feb 15.
16. Simard LR, Belanger MC, Morissette S., et al. Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with spinal muscular atrophy. Neurology. 2007;68:451-456.
17. Parano E., Pavone L., Falsaperla R., et al. Molecular basis of phenotypic heterogeneity in siblings with spinal muscular atrophy. Ann Neurol. 1996;40:247-251.
18. Lorson CL, Androphy EJ An exonic enhancer is required for inclusion of an essential exon in the spinal muscular atrophy-determining gene SMN. Hum Mol Genet. 2000;9:259-265.
19. Cartegni L., Krainer AR Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. 2002;30:377-384.
20. Kashima T., Manley JL A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet. 2003;34:460-463.
21. Cartegni L., Krainer AR Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol. 2003;10:120-125.
22. Cartegni L., Hastings ML, Calarco JA, et al. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet. 2006;78:63-77.
23. Hofmann Y., Lorson CL, Stamm S., et al. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci U S A. 2000;97:9618-9623.
24. Hofmann Y., Wirth B. hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1. Hum Mol Genet. 2002;11:2037-2049.
25. Young PJ, DiDonato CJ, Hu D., et al. SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2 beta 1. Hum Mol Genet. 2002;11:577-587.
26. Miyajima H., Miyaso H., Okumura M., et al. Identification of a cisacting element for the regulation of SMN exon 7 splicing. J Biol Chem. 2002;277:23271-23277.
27. Miyaso H., Okumura M., Kondo S., et al. An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA. J Biol Chem. 2003;278:15825-15831.
28. Singh NN, Androphy EJ, Singh RN In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. RNA. 2004;10:1291-1305.
29. Singh NK, Singh NN, Androphy EJ, Singh RN Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. 2006;26:1333-1346.
30. Liu Q., Fischer U., Wang F., Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell. 1997;90:1013-1021.
31. Patrizi AL, Tiziano F., Zappata S., et al. SMN protein analysis in fibroblast, amniocyte and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis. Eur J Hum Genet. 1999;7:301-309.
32. Zhang HL, Pan F., Hong D., et al. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J Neurosci. 2003;23:6627-6637.
33. Zhang H., Xing L., Rossoll W., et al. Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons. J Neurosci. 2006;26:8622-8632.
34. Rossoll W., Jablonka S., Andreassi C., et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol. 2003;163:801-812.
35. Broccolini A., Engel WK, Askanas V. Localization of survival motor neuron protein in human apoptotic-like and regenerating muscle fibers, and neuromuscular junctions. Neuroreport. 1999;10:1637-1641.
36. La Bella V., Cisterni C., Salaun D., Pettmann B. Survival motor neuron (SMN) protein in rat is expressed as different molecular forms and is developmentally regulated. Eur J Neurosci. 1998;10:2913-2923.
37. Jablonka S., Bandilla M., Wiese S., et al. Co-regulation of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in spinal muscular atrophy. Hum Mol Genet. 2001;10:497-505.
38. Kernochan LE, Russo ML, Woodling NS, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet. 2005;14:1171-1182.
39. Paushkin S., Gubitz AK, Massenet S., Dreyfuss G. The SMN complex, an assemblyosome of ribonucleoproteins. Curr Opin Cell Biol. 2002;14:305-312.
40. Otter S., Grimmler M., Neuenkirchen N., Chari A., et al. A comprehensive interaction map of the human SMN-complex. J Biol Chem. 2007;282;5825-5833. Epub Dec 18, 2006.
41. Lorson CL, Strasswimmer J., Yao JM, et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet. 1998;19:63-66.
42. Cifuentes-Diaz C., Frugier T., Tiziano FD, et al. Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy. J Cell Biol. 2001;152:1107-1114.
43. Le TT, Pham LT, Butchbach ME, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet. 2005;14:845-857.
44. Yong J., Wan L., Dreyfuss G. Why do cells need an assembly machine for RNA-protein complexes? Trends Cell Biol. 2004;14:226-232.
45. Will CL, Luhrmann R. Spliceosomal UsnRNP biogenesis, structure and function. Curr Opin Cell Biol. 2001;13:290-301.
46. McWhorter ML, Monani UR, Burghes AH, Beattie CE Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol. 2003;162:919-931.
47. Miguel-Aliaga I., Culetto E., Walker DS, et al. The Caenorhabditis elegans orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability. Hum Mol Genet. 1999;8:2133-2143.
48. Miguel-Aliaga I., Chan YB, Davies KE, van den Heuvel M. Disruption of SMN function by ectopic expression of the human SMN gene in Drosophila. FEBS Lett. 2000;486:99-102.
49. Schrank B., Gotz R., Gunnersen JM, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A. 1997;94:9920-9925.
50. Hsieh-Li HM, Chang JG, Jong YJ, et al. A mouse model for spinal muscular atrophy. Nat Genet. 2000;24:66-70.
51. Monani UR, Pastore MT, Gavrilina TO, et al. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol. 2003;160:41-52.
52. Wan L., Battle DJ, Yong J., et al. The survival of motor neurons protein determines the capacity for snRNP assembly: Biochemical deficiency in spinal muscular atrophy. Mol Cell Biol. 2005;25:5543-5551.
53. Winkler C., Eggert C., Gradl D., et al. Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev. 2005;19:2320-2330.
54. Carrel TL, McWhorter ML, Workman E., et al. Survival motor neuron function in motor axons is independent of functions required for small nuclear ribonucleoprotein biogenesis. J Neurosci. 2006;26:11014-11022.
55. Wharton, S., Ince PG Pathology of motor neuron disorders. In: Shaw PJ, Strong MJ, eds. Motor Neuron Disorders. Philadelphia, PA: Butterworth Heinemann; 2003:17-49.
56. Fidzianska A., Goebel HH, Warlo I. Acute infantile spinal muscular atrophy. Muscle apoptosis as a proposed pathogenetic mechanism. Brain. 1990;113(Pt 2):433-445.
57. Soubrouillard C., Pellissier JF, Lepidi H., et al. Expression of developmentally regulated cytoskeleton and cell surface proteins in childhood spinal muscular atrophies. J Neurol Sci. 1995;133:155-163.
58. Arnold AS, Gueye M., Guettier-Sigrist S., et al. Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients. Lab Invest. 2004;84:1271-1278.
59. Shafey D., Cote PD, Kothary R. Hypomorphic Smn knockdown C2C12 myoblasts reveal intrinsic defects in myoblast fusion and myotube morphology. Exp Cell Res. 2005;311:49-61.
60. Braun S., Croizat B., Lagrange MC, et al. Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet. 1995;345:694-695.
61. Nicole S., Desforges B., Millet G., et al. Intact satellite cells lead to remarkable protection against Smn gene defect in differentiated skeletal muscle. J Cell Biol. 2003;161:571-582.
62. Chan YB, Miguel-Aliaga I., Franks C., et al. Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum Mol Genet. 2003;12:1367-1376.
63. Funakoshi H., Belluardo N., Arenas E., et al. Muscle-derived neurotrophin-4 as an activity-dependent trophic signal for adult motor neurons. Science. 1995;268:1495-1499.
64. Sumner CJ Therapeutics development for spinal muscular atrophy. NeuroRx. 2006;3:235-245.
65. Minucci S., Pelicci PG Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51.
66. Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001;98:9808-9813.
67. Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54:647-654.
68. Brichta L., Hofmann Y., Hahnen E., et al. Valproic acid increases the SMN2 protein level: A well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003;12:2481-2489.
69. Andreassi C., Angelozzi C., Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: Relevance for treatment of spinal muscular atrophy. Eur J Hum Genet. 2004;12:59-65.
70. Avila A., Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007;117:659-671.
71. Hirtz D., Iannaccone S., Heemskerk J., et al. Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology. 2005;65:1352-1357.
72. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology. 2006;67:500-501.
73. Mercuri E., Bertini E., Messina S., et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology. 2007;68:51-55.
74. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497-1511.